Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

Similar articles for PubMed (Select 17308118)

1.

Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.

Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK.

Cancer Res. 2007 Feb 15;67(4):1757-68.

2.

Gene alterations in tumor-associated endothelial cells from endometrial cancer.

Du XL, Jiang T, Zhao WB, Wang F, Wang GL, Cui M, Wen ZQ.

Int J Mol Med. 2008 Nov;22(5):619-32.

PMID:
18949382
3.

Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.

Song J, Shih IeM, Chan DW, Zhang Z.

Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614.

4.

Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.

Grisaru D, Hauspy J, Prasad M, Albert M, Murphy KJ, Covens A, Macgregor PF, Rosen B.

Oncol Rep. 2007 Dec;18(6):1347-56.

PMID:
17982616
6.

Screening for genes associated with ovarian cancer prognosis.

Chang XH, Zhang L, Yang R, Feng J, Cheng YX, Cheng HY, Ye X, Fu TY, Cui H.

Chin Med J (Engl). 2009 May 20;122(10):1167-72.

PMID:
19493465
7.

Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium.

Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M.

BMC Genomics. 2008 Apr 30;9:201. doi: 10.1186/1471-2164-9-201.

8.

Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT).

Sodek KL, Evangelou AI, Ignatchenko A, Agochiya M, Brown TJ, Ringuette MJ, Jurisica I, Kislinger T.

Mol Biosyst. 2008 Jul;4(7):762-73. doi: 10.1039/b717542f. Epub 2008 Apr 17.

PMID:
18563251
9.

Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.

Ria R, Todoerti K, Berardi S, Coluccia AM, De Luisi A, Mattioli M, Ronchetti D, Morabito F, Guarini A, Petrucci MT, Dammacco F, Ribatti D, Neri A, Vacca A.

Clin Cancer Res. 2009 Sep 1;15(17):5369-78. doi: 10.1158/1078-0432.CCR-09-0040. Epub 2009 Aug 18.

10.

Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.

Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):690-700.

11.

Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.

Chien J, Fan JB, Bell DA, April C, Klotzle B, Ota T, Lingle WL, Gonzalez Bosquet J, Shridhar V, Hartmann LC.

Gynecol Oncol. 2009 Jul;114(1):3-11. doi: 10.1016/j.ygyno.2009.04.002. Epub 2009 May 1.

PMID:
19410283
12.

Gene expression in epithelial ovarian carcinoma.

Matei D, Graeber TG, Baldwin RL, Karlan BY, Rao J, Chang DD.

Oncogene. 2002 Sep 12;21(41):6289-98.

13.

Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.

Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, Hajduch M, Murray P, Kolar Z.

BMC Cancer. 2007 Mar 27;7:55.

14.

RUNX3 protein is overexpressed in human epithelial ovarian cancer.

Nevadunsky NS, Barbieri JS, Kwong J, Merritt MA, Welch WR, Berkowitz RS, Mok SC.

Gynecol Oncol. 2009 Feb;112(2):325-30. doi: 10.1016/j.ygyno.2008.09.006. Epub 2008 Oct 19.

PMID:
18937968
15.

Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.

Yanagie H, Hisa T, Ogata A, Miyazaki A, Nonaka Y, Nishihira T, Osada I, Sairennji T, Sugiyama H, Furuya Y, Kidani Y, Takamoto S, Takahashi H, Eriguchi M.

Biomed Pharmacother. 2009 Sep;63(8):553-60. doi: 10.1016/j.biopha.2008.04.006. Epub 2008 May 27.

PMID:
18571892
16.

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.

Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR.

Clin Cancer Res. 2005 May 15;11(10):3686-96.

17.

Transcriptome profiling and network pathway analysis of genes associated with invasive phenotype in oral cancer.

Kang CJ, Chen YJ, Liao CT, Wang HM, Chang JT, Lin CY, Lee LY, Wang TH, Yen TC, Shen CR, Chen IH, Chiu CC, Cheng AJ.

Cancer Lett. 2009 Nov 1;284(2):131-40. doi: 10.1016/j.canlet.2009.04.014. Epub 2009 May 19.

PMID:
19457608
18.

Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers.

Smalley MJ, Iravani M, Leao M, Grigoriadis A, Kendrick H, Dexter T, Fenwick K, Regan JL, Britt K, McDonald S, Lord CJ, Mackay A, Ashworth A.

Breast Cancer Res. 2007;9(6):R85.

19.

Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, Santin AD.

Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11.

PMID:
17346539
20.

Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens.

Euer NI, Kaul S, Deissler H, Möbus VJ, Zeillinger R, Weidle UH.

Oncol Rep. 2005 Mar;13(3):375-87.

PMID:
15706405
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk